Thymoma and thymic carcinoma: Molecular pathology and targeted therapy

Journal of Thoracic Oncology

Volumn 5, Issue 10 SUPPL. 4, 2010, Pages

  Ströbel, Philipp ^a   Hohenberger, Peter ^a   Marx, Alexander ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Multitargeted kinase inhibitors; Targeted therapies; Thymic carcinomas

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; SORAFENIB; SUNITINIB;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; LYMPHOCYTE; MOLECULAR GENETICS; MYASTHENIA GRAVIS; ONCOGENE C KIT; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; THYMOMA; THYMUS CANCER; THYMUS CARCINOMA;

EID: 77957583341     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f209a8     Document Type: Article

References (50)

1. Müller-Hermelink HK, Engel P, Kuo TT, et al. Tumours of the thymus: Introduction. In MD Travis, E Brambilla, HK Müller-Hermelink, et al. (Eds.), World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Thymus and Heart. Lyon, France: IARC Press, 2004. Pp. 145-151.
2. Strobel P, Chuang WY, Chuvpilo S, et al. Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. Ann NY Acad Sci 2008;1132:143-156.
3. Strobel P, Murumagi A, Klein R, et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol 2007;211:563-571.
4. Scarpino S, Di Napoli A, Stoppacciaro A, et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol 2007;149:504-512.
5. Nenninger R, Schultz A, Hoffacker V, et al. Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas. Lab Invest 1998;78:743-753.
6. Kadota Y, Okumura M, Miyoshi S, et al. Altered T cell development in human thymoma is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-gamma). Clin Exp Immunol 2000;121:59-68.
7. Chalabreysse L, Roy P, Cordier JF, et al. Correlation of the WHO schema for the classification of thymic epithelial neoplasms with prognosis: a retrospective study of 90 tumors. Am J Surg Pathol 2002;26: 1605-1611.
8. Engel P, Marx A, Muller-Hermelink HK. Thymic tumours in Denmark. A retrospective study of 213 cases from 1970-1993. Pathol Res Pract 1999;195:565-570.
9. Okumura M, Miyoshi S, Fujii Y, et al. Clinical and functional significance of WHO classification on human thymic epithelial neoplasms: a study of 146 consecutive tumors. Am J Surg Pathol 2001;25:103-110.
10. Kondo K, Monden Y. Thymoma and myasthenia gravis: a clinical study of 1,089 patients from Japan. Ann Thorac Surg 2005;79:219-224.
11. Inoue M, Starostik P, Zettl A, et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003;63:3708-3715.
12. Ho FC, Fu KH, Lam SY, et al. Evaluation of a histogenetic classification for thymic epithelial tumours. Histopathology 1994;25:21-29.
13. Strobel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004;22:1501-1509.
14. Margaritora S, Cesario A, Cusumano G, et al. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 2010;89:245-252; discussion 252.
15. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002;95:420-429.
16. Quintanilla-Martinez L, Wilkins EW Jr, Choi N, et al. Thymoma. Histologic subclassification is an independent prognostic factor. Cancer 1994;74:606-617.
17. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48: 2485-2492.
18. Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004;130:222-224.
19. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004;202: 375-381.
20. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004;22:4514-4522.
21. Zettl A, Strobel P, Wagner K, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000;157:257-266.
22. Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009;15:6790-6799.
23. Inoue M, Marx A, Zettl A, et al. Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am J Pathol 2002;161:1507-1513.
24. Zhou R, Zettl A, Strobel P, et al. Thymic epithelial tumors can develop along two different pathogenetic pathways. Am J Pathol 2001;159: 1853-1860.
25. Müller-Hermelink HK, Strobel P, Zettl A, et al. Metastases to thymus and anterior mediastinum. In MD Travis, E Brambilla, HK Müller-Hermelink, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Thymus and Heart. Lyon, France: IARC Press, 2004. Pp. 247.
26. Kurup A, Loehrer PJ Sr. Thymoma and thymic carcinoma: therapeutic approaches. Clin Lung Cancer 2004;6:28-32.
27. Loehrer PJ Sr, Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 1997;15:3093-3099.
28. Loehrer PJ Sr, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994;12:1164-1168.
29. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006;33:407-420.
30. Rutkowski P, Ruka W. Emergency surgery in the era of molecular treatment of solid tumours. Lancet Oncol 2009;10:157-163.
31. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with over-expression of mutated KIT and the response to imatinib. N Engl J Med 2004;350:2625-2626.
32. Strobel P, Knop S, Einsele H, et al. [Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic perspective]. Verh Dtsch Ges Pathol 2007;91:177-186.
33. Tsuchida M, Umezu H, Hashimoto T, et al. Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer 2008;62:321-325.
34. Yoh K, Nishiwaki Y, Ishii G, et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008;62:316-320.
35. Kertesz GP, Hauser P, Varga P, et al. Advanced pediatric inoperable thymus carcinoma (type C thymoma): case report on a novel therapeutic approach. J Pediatr Hematol Oncol 2007;29:774-775.
36. Salter J, Lewis D, Yiannoutsos C, et al. Imatinib for the treatment of thymic carcinoma. J Clin Oncol 2008;26(Suppl):Abstract 8116.
37. Giaccone G, Rajan A, Ruijter R, et al. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 2009;4: 1270-1273.
38. Henley JD, Koukoulis GK, Loehrer PJ Sr. Epidermal growth factor receptor expression in invasive thymoma. J Cancer Res Clin Oncol 2002;128:167-170.
39. Ionescu DN, Sasatomi E, Cieply K, et al. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005;103:630-636.
40. Christodoulou C, Murray S, Dahabreh J, et al. Response of malignant thymoma to erlotinib. Ann Oncol 2008;19:1361-1362.
41. Farina G, Garassino MC, Gambacorta M, et al. Response of thymoma to cetuximab. Lancet Oncol 2007;8:449-450.
42. Palmieri G, Marino M, Salvatore M, et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 2007;12:757-761.
43. Bedano P, Perkins S, Burns M, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2008;26(Suppl):Abstract 19087.
44. Kurup A, Burns M, Dropcho S, et al. Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 2005;23(16 Suppl):Abstract 7068.
45. Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006;407:597-612.
46. Li XF, Chen Q, Huang WX, et al. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 2009;26:157-160.
47. Faivre S, Demetri G, Sargent W, et al. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6: 734-745.
48. Strobel P, Bargou R, Wolff A, et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010;103:196-200.
49. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
50. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-896.